New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: A case report and literature review

Clinical Rheumatology

Volumn 32, Issue 2, 2013, Pages 271-275

  Matsumoto, Takumi ^a   Nakamura, Ichiro ^a,b   Miura, Ayumi ^a   Momoyama, Gen ^a   Ito, Katsumi ^a  

^a Yugawara   (Japan)

^b MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

Adalimumab; Demyelination; Magnetic resonance imaging (MRI); Multiple sclerosis; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; AUROTHIOMALATE; BICARBONATE; BUCILLAMINE; GADOLINIUM; METHOTREXATE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PENTETIC ACID; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID;

ABDUCENS NERVE PARALYSIS; AGED; ATAXIA; BRAIN DAMAGE; CASE REPORT; CATARACT EXTRACTION; DIPLOPIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL PNEUMONIA; MULTIPLE SCLEROSIS; NEUROLOGIC GAIT DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PTOSIS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT DURATION; WHITE MATTER LESION;

EID: 84877721777     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2113-2     Document Type: Review

References (21)

1. Scheinfeld N (2004) A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 15:280-294
2. Lozeron P, Denier C, Lacroix C, Adams D (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66:490-497
3. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292-302
4. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44:2862-2869
5. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889-894
6. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472
7. Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF (1991) Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol 147:1522-1529
8. Selmaj KW, Raine CS (1995) Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 45:S44-S49
9. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531-1534
10. Group TLMSSGaTUoBCMMA (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53:457-465
11. Toussirot E, Pertuiset E, Martin A, Melac-Ducamp S, Alcalay M, Grardel B, Seror P, Perdriger A, Wendling D, Mulleman D, Beraneck L, Mariette X (2006) Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. J Rheumatol 33:1027-1028
12. Tanno M, Nakamura I, Kobayashi S, Kurihara K, Ito K (2006) New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 25:929-933
13. Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57:1885-1888
14. Titelbaum DS, Degenhardt A, Kinkel RP (2005) Anti-tumor necrosis factor alpha-associated multiple sclerosis. AJNR Am J Neuroradiol 26:1548-1550
15. Al Saieg N, Luzar MJ (2006) Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol 33:1202-1204
16. Bensouda-Grimaldi L, Mulleman D, Valat JP, Autret-Leca E (2007) Adalimumab-associated multiple sclerosis. J Rheumatol 34:239-240, discussion 240
17. Gomez-Gallego M, Meca-Lallana J, Fernandez-Barreiro A (2008) Multiple sclerosis onset during etanercept treatment. Eur Neurol 59:91-93
18. Davis SA, Johnson RR, Pendleton JW (2008) Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies. J Rheumatol 35:1469-1470
19. Pfueller CF, Seipelt E, Zipp F, Paul F (2008) Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol 37:397-399
20. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T (2009) Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45:55-57
21. Cruz Fernandez-Espartero M, Perez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gomez-Reino JJ, Carmona L (2011) Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 41:524-533